Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.92 USD | +7.45% | -0.86% | +177.82% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 6.29M | Capitalization | 308M |
---|---|---|---|---|---|
Net income 2024 * | -71M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | 217M | Net cash position 2025 * | - | EV / Sales 2025 * | 49 x |
P/E ratio 2024 * |
-4.1
x | P/E ratio 2025 * |
-5.15
x | Employees | 45 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.36% |
Latest transcript on Jasper Therapeutics, Inc.
1 day | +7.45% | ||
1 week | -0.86% | ||
Current month | -25.34% | ||
1 month | -22.54% | ||
3 months | +88.64% | ||
6 months | +208.08% | ||
Current year | +177.82% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Herbert Cross
DFI | Director of Finance/CFO | 52 | 23-09-21 |
Luca Di Noto
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald Martell
CEO | Chief Executive Officer | 62 | 22-03-14 |
Thomas Wiggans
CHM | Chairman | 72 | Oct. 31 |
Kurt von Emster
BRD | Director/Board Member | 56 | 21-09-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 20.4 | -3.68% | 52,241 |
24-04-25 | 21.18 | -3.86% | 72,554 |
24-04-24 | 22.03 | -0.36% | 44,701 |
24-04-23 | 22.11 | -1.82% | 77,665 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+177.82% | 308M | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- JSPR Stock